Saturday - September 25, 2021
University of Texas's MD Anderson Cancer: Metabolic Inhibitor IACS-6274 Shows Early Antitumor Effects in Underserved Patients With Advanced Cancers
May 19, 2021
HOUSTON, Texas, May 19 (TNSRes) -- The University of Texas's MD Anderson Cancer Center issued the following news release:

The glutaminase (GLS1) inhibitor IACS-6274, discovered and developed by The University of Texas MD Anderson Cancer Center's Therapeutics Discovery division, appears to be well-tolerated with successful target inhibition and early signs of anti-tumor activity in a biomarker-driven Phase I trial. Interim results of the study will be presented at the 2021 American S . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation
Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products